Two Sigma Investments LP Purchases 90,197 Shares of Progyny, Inc. (NASDAQ:PGNY)

Two Sigma Investments LP increased its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 15.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 657,276 shares of the company's stock after purchasing an additional 90,197 shares during the period. Two Sigma Investments LP owned approximately 0.77% of Progyny worth $11,338,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Barclays PLC boosted its holdings in Progyny by 530.4% in the third quarter. Barclays PLC now owns 706,157 shares of the company's stock worth $11,835,000 after purchasing an additional 594,140 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in Progyny by 52.2% in the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock worth $22,989,000 after purchasing an additional 456,853 shares in the last quarter. Vanderbilt University bought a new stake in Progyny in the fourth quarter worth $254,000. Janney Montgomery Scott LLC bought a new stake in Progyny in the fourth quarter worth $1,124,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Progyny by 129.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,967 shares of the company's stock worth $344,000 after purchasing an additional 11,268 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PGNY. Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group decreased their price target on shares of Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a report on Monday, May 12th. Finally, BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a report on Monday, March 31st. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $23.45.

Progyny Trading Up 0.7%

NASDAQ:PGNY traded up $0.16 during mid-day trading on Thursday, hitting $21.41. The company's stock had a trading volume of 160,940 shares, compared to its average volume of 1,704,088. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $30.42. The stock has a fifty day moving average of $22.10 and a 200-day moving average of $20.02. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 36.92, a P/E/G ratio of 2.39 and a beta of 1.37.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. During the same quarter last year, the firm posted $0.17 EPS. The business's revenue was up 16.5% on a year-over-year basis. On average, equities analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.